HC Wainwright Issues Positive Outlook for Absci Earnings

Absci Co. (NASDAQ:ABSI) – Investment analysts at HC Wainwright increased their Q2 2025 earnings per share estimates for Absci in a research report issued to clients and investors on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.23) per share for the quarter, up from their prior forecast of ($0.28). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Absci’s current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Absci’s Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.64) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.28) EPS and FY2029 earnings at $0.02 EPS.

Several other brokerages also recently weighed in on ABSI. KeyCorp increased their price target on Absci from $5.00 to $9.00 and gave the stock an “overweight” rating in a report on Wednesday, April 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of Absci in a research report on Wednesday. Finally, Guggenheim reaffirmed a “buy” rating and set a $10.00 target price on shares of Absci in a research report on Thursday, March 20th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Absci has an average rating of “Buy” and a consensus price target of $8.40.

Absci Trading Down 2.7%

Shares of ABSI stock opened at $2.88 on Friday. Absci has a 1 year low of $2.01 and a 1 year high of $6.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. The stock’s 50 day simple moving average is $2.87 and its two-hundred day simple moving average is $3.34. The company has a market cap of $367.34 million, a PE ratio of -3.10 and a beta of 2.19.

Absci (NASDAQ:ABSI) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%. The business had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.07 million.

Institutional Trading of Absci

Institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC raised its stake in Absci by 32.5% in the 1st quarter. ARK Investment Management LLC now owns 10,955,089 shares of the company’s stock worth $27,497,000 after acquiring an additional 2,689,153 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new position in Absci in the 1st quarter worth $5,792,000. Royce & Associates LP raised its stake in Absci by 472.1% in the 4th quarter. Royce & Associates LP now owns 882,096 shares of the company’s stock worth $2,311,000 after acquiring an additional 727,905 shares during the last quarter. Nuveen LLC purchased a new position in Absci in the 1st quarter worth $1,251,000. Finally, Two Sigma Advisers LP raised its stake in Absci by 191.9% in the 4th quarter. Two Sigma Advisers LP now owns 676,400 shares of the company’s stock worth $1,772,000 after acquiring an additional 444,700 shares during the last quarter. Institutional investors and hedge funds own 52.05% of the company’s stock.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.